THE LEVEL OF ANTI-TPO ANTIBODIES IN IBD PATIENTS: A CASE SERIES

AA RAHMAN; M WAQAS; Z MOHSIN; Z HAMEED; M JUNAID; . SHERBANO; G SIRI

doi:10.54112/bcsrj.v2024i1.970

Authors

AA RAHMAN Tehran University of Medical Sciences, Iran
M WAQAS Vogue Esthetics Islamabad, Pakistan
Z MOHSIN Shifa College of Medicine, Islamabad, Pakistan
Z HAMEED Shifa College of Medicine, Islamabad, Pakistan
M JUNAID Shifa College of Medicine, Islamabad, Pakistan
. SHERBANO Shifa Tameer e Millat University, Islamabad, Pakistan
G SIRI Tehran University of Medical Sciences, Iran

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.970

Keywords:

Anti-TPO Antibodies, Crohn’s Disease, Inflammatory Bowel Diseases, Thyroid Function, Ulcerative Colitis

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions characterized by intestinal inflammation. Autoimmune thyroid diseases (AITDs), such as those involving anti-thyroid peroxidase (anti-TPO) antibodies, have been noted as common comorbidities in IBD patients. Despite this, comprehensive data on anti-TPO antibodies' prevalence and clinical significance in IBD, particularly about disease type and location, remain limited. Objective: This study aims to determine the prevalence of anti-TPO antibodies among patients with IBD, primarily focusing on UC, and to compare these findings with the prevalence of anti-TPO antibodies in the general Iranian population. Methods: A cross-sectional study was conducted at Amir Alam Hospital, Tehran University of Medical Sciences, in 2022. The study included 98 patients diagnosed with IBD, using convenient sampling. Gender, age, anti-TPO levels, Free T4, and TSH were measured through questionnaires, serological tests, and imaging. Statistical analyses involved descriptive statistics, Chi-square tests, Pearson correlation coefficients, independent samples t-tests, and ANOVA, performed using SPSS software. Results: No significant differences were observed in anti-TPO levels between genders (p = 0.844). Additionally, no significant difference was found in Free T4 and TSH levels based on gender (p = 0.396 and p = 0.260, respectively). A significant correlation was identified between TSH levels and disease location (p < 0.05), while anti-TPO levels showed no significant correlation with disease type or location. Conclusion: The prevalence of anti-TPO antibodies in IBD patients was notable, with no significant differences observed between UC and CD or between genders. The study underscores the importance of regular thyroid function monitoring in IBD patients, particularly considering the significant association between TSH levels and disease location. Further research is needed to explore the underlying mechanisms and clinical implications of thyroid dysfunction in IBD.

Downloads

Download data is not yet available.

References

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. Journal of inflammation research. 2014:113-20.

Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54. e42.

Fallahi G-H, Moazzami K, Tabatabaeiyan M, Zamani MM, Asgar-Shirazi M, Najafi M, et al. Clinical characteristics of Iranian pediatric patients with inflammatory bowel. Acta Gastro-Enterol Belg. 2009;72.

Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. Journal of autoimmunity. 2009;33(3-4):197-207.

McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252-65.

Marcocci C, Marino M. Thyroid directed antibodies. Werner and Ingbar's the thyroid: a fundamental and clinical text. 9: Lippincott Williams &Wilkins; 2005. p. 360-72.

Casella G, De Marco E, Antonelli E, Daperno M, Baldini V, Signorini S, et al. The prevalence of hyper-and hypothyroidism in patients with ulcerative colitis. Journal of Crohn's and Colitis. 2008;2(4):327-30.

Järnerot G, Khan AA, Truelove S. The thyroid in ulcerative colitis and Crohn's Disease: II. Thyroid enlargement and hyperthyroidism in ulcerative colitis. Acta Medica Scandinavica. 1975;197(1‐6):83-7.

Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F, et al. Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recycling. Journal of Crohn's and Colitis. 2017;11(8):999-1010.

Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, et al. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. The Journal of Clinical Endocrinology & Metabolism. 2006;91(6):2205-8.

Yakut M. Thyroid disorders in patients with inflammatory bowel diseases. 2011.

Ramai D, Bivona A, Latson W, Ofosu A, Ofori E, Reddy M, et al. Endoscopic management of tracheoesophageal fistulas. Annals of gastroenterology. 2019;32(1):24.